Larimar Therapeutics director Thomas Edward Hamilton acquires USD 166,890 of common sharesPUBT·Jul 8 at 03:06 PMLRMR+5.37%
20:11 ETINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Larimar Therapeutics, Inc. - LRMRprnewswire·Jul 1 at 07:15 PMLRMR+5.37%
Nomlabofusp Progress and Durable Efficacy Support Buy Rating on LRMR with Unchanged $25 Price TargetTip Ranks·Jun 29 at 11:15 AMLRMR+5.37%
LRMR: Nomlabofusp shows sustained efficacy and safety in FA, with BLA submission and phase III underwayQuartr·Jun 29 at 09:24 AMLRMR+5.37%
Larimar Stock Slides 15% Despite FDA Backing Rolling Submission For Rare Disease Drugbenzinga_article·Jun 29 at 09:15 AMLRMR+5.37%
Biohaven, Goodyear Tire And Other Big Stocks Moving Lower In Monday’s Pre-Market Sessionbenzinga_article·Jun 29 at 07:11 AMGT-2.75%TOST+0.77%
12 Health Care Stocks Moving In Monday's Pre-Market Sessionbenzinga_article·Jun 29 at 07:05 AMJUNS-1.52%UPC+6.91%
LRMR: Nomlabofusp shows sustained FXN increases, clinical benefit, and advances toward accelerated approvalQuartr·Jun 29 at 05:36 AMLRMR+5.37%
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia | LRMR Stock NewsStockTitan·Jun 28 at 09:30 PMLRMR+5.37%
